A Comparison of Fremanezumab and Eptinezumab in the Prevention of Chronic Episodic Migraine

Chronic migraine is a disorder that affects millions worldwide. Research indicates that people suffering from chronic migraine respond well to monoclonal antibody treatment aimed at characteristic immune cell markers. By targeting immune cell markers, the immune system is subsequently suppressed in a way such that disease activity is decreased. Monoclonal antibody treatments targeted towards a variety of immune cell markers have historically been shown to result in decreases in chronic migraine disease activity. Many studies have assessed disease activity with monoclonal antibody treatments, but few have compared different treatments. A systematic review of a study that assessed the migraine activity using mean monthly migraine days (MMDs) for those taking fremanezumab was then compared to the findings of another study which assessed the MMDs with those taking eptinezumab The patients treated with fremanezumab had significantly decreased MMDs when compared with other matched controls. Those who were treated with fresolimumab had significantly decreased MMDs when compared with other matched controls. However, those who were treated with eptinezumab had a greater reduction of MMDs as compared to control groups than did those who were treated with fremanezumab. Monoclonal antibody treatments for chronic migraine are widespread. It is critical that these treatments are compared in order to find those with the greatest efficacy. For this review, eptinezumab seemed to have a greater reduction of disease activity than did fremanezumab. Further studies with greater sample sizes are needed to conclude which has greater efficacy.